



3. Synergies in the development of New Diagnostics, Drugs and Vaccines for Tuberculosis Friday, 28 October 2011, 16:45-18:45, Room Faidherbe

Symposium organised by the Stop TB Partnership's Working Groups on New Diagnostics, New Drugs and New Vaccines

Description: The purpose of this session is to discuss areas of synergy between the new tools in the global response to TB and the pathway for development of new tools, and to bring together the new TB tools community along with researchers in early discovery to discuss common issues and identify areas for collaboration and partnership among multiple sectors. The session will begin with a review of data modeling studies showing the potential impact of current new tools being developed or implemented for TB, including new drugs, diagnostics and vaccines. Following, the topics will focus on the work of the Stop TB Partnership's New Tools Working Groups (Diagnostics, Drugs, and Vaccines) and their continued contribution to the objectives set forth in the Global Plan to Stop TB. The session also will cover the process of development of new tools presenting data on the research in biomarkers and correlates of protection and requirements and issues around clinical testing and integration of diagnostics. This symposium marks a new initiative from the 3 new tools Working Groups of the Stop TB Partnership to exchange on scientific and technical activities and find novel methods to synergize efforts.

Relation to conference theme: The development of new diagnostics, drugs, and vaccines is imperative to controlling and eliminating the burden of TB globally. To move a new tool from bench to bedside necessitates new partnerships of all kinds and from different sectors. Investments will be required from both the private and public sector for successful development and implementation. The joining of the new tools groups demonstrates a willingness to collaborate and an understanding that coming together around areas of common interest can be beneficial to the success in reaching individual objectives.

Objectives:

- To highlight the achievements and potential impact of new diagnostics, drugs and vaccines on the burden of tuberculosis globally
- To highlight the contributions and current initiatives of the three New Tools Working Groups (Diagnostics, Drugs and Vaccines)
- To provide an overview of the latest research on biomarkers and correlates of protection and their role in the development of new tools for TB
- To discuss the needs, challenges and opportunities for conducting registration-type clinical trials including the vital role of the affected communities
- To explore considerations for integrating new diagnostics into the clinical development of new drug regimens and new vaccines

Target audience: This session is targeted towards a broad audience interested in research and development of new tools for tuberculosis. This may include researchers, developers, clinicians, regulatory affairs people, government representatives, donors and other implementers.

Keywords: TB diagnostics; TB vaccines; TB drugs and treatment; clinical trial site capacity; Stop TB Partnership

Coordinators: Alessandra Varga (FIND and Working Group on New Diagnostics), Cherise Scott (Global Alliance for TB Drug Development and Working Group on New Drugs), Jennifer Woolley (Aeras and Working Group on New Vaccines), Christian Lienhardt (Stop TB Partnership)

Chairs: Giorgio Roscigno, Working Group on New Diagnostics (Ethiopia), Michel Greco, Working Group on New Vaccines (France), Mel Spigelman, Working Group on New Drugs (USA)

<i>Presentations</i>	<i>Speakers</i>
The need for new tools for TB and their potential epidemiological impact	<i>Christian Lienhardt, Stop TB Partnership (Switzerland)</i>
Contributions and current projects of the New Tools Working Groups (Diagnostics, Drugs, and Vaccines)	<i>Giorgio Roscigno, Working Group on New Diagnostics (Ethiopia)</i> <i>Michel Greco, Working Group on New Vaccines (France)</i> <i>Mel Spigelman, Working Group on New Drugs (USA)</i>
Update on current research in biomarkers and correlates of protection	<i>Hazel Dockrell, London School of Hygiene and Tropical Medicine (UK)</i>
Maximizing resources and partnerships for the conduct of registration trials for drugs, vaccines and diagnostics	<i>Barbara Laughon, National Institute of Allergy and Infectious Diseases/National Institutes of Health, NIAID/NIH (USA)</i>
Subtopic: critical role of the community in conduct of registration trials for drugs, vaccines, diagnostics	<i>Mayowa Joel, Community Representative to the Working Group on New Diagnostics (Nigeria)</i>
Integration of new diagnostics into TB drug and vaccine clinical trials	<i>Michael Hoelscher, Ludwig-Maximilians University, Munich, Germany and Mbeya Medical Research Programme (Tanzania)</i>